FIELD: medicine.
SUBSTANCE: invention can be used for obtaining diagnostic and/or therapeutic agents, in particular antibodies, which specifically interact with proteins of cell surface of target cells. Claimed is method of screening phage display library and including it method of isolation of library element, which is specific partner of binding of target cell surface protein, and method of isolation of unknown cell surface protein, specifically interacting with library element. Method of screening phage display library according to invention includes contact of said library with cells of interest with further separation of cells, which bound with one or several elements of expression library, from non-bound elements by separation through organic phase, and differs by introduction of additional stage, which consists in carrying out before said separation of at least one stage of material washing, and ensures essential increase of method efficiency.
EFFECT: higher efficiency.
30 cl, 7 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCREENING METHODS AND THEIR APPLICATION | 2012 |
|
RU2622089C2 |
| BINDING ELEMENTS WITH MODIFIED DIVERSIFIED BACKBONE DOMAINS | 2017 |
|
RU2778694C2 |
| NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
| METHOD FOR IDENTIFICATION OF BACTERIOPHAGE, METHOD FOR ISOLATION OF MAMMAL CELLS, METHOD FOR SELECTION OF BACTERIOPHAGE (VARIANTS), METHOD FOR IDENTIFICATION OF BACTERIOPHAGE SUBGROUP AND INTERNALIZING LIGAND (VARIANTS) | 1998 |
|
RU2234530C2 |
| SPARC-BINDING PEPTIDES AND USING THEM | 2009 |
|
RU2491085C2 |
| RECEPTORS-MEDIATED DELIVERY OF GENES BY USING VECTORS BASED UPON BACTERIOPHAGES | 1998 |
|
RU2209088C2 |
| NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR | 2001 |
|
RU2268068C2 |
| PARTNERS OF SPECIFIC BINDING WITH NGF | 2006 |
|
RU2406728C2 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| ANTIBODY OR ITS ANTI-BINDING FRAGMENT, WHICH IS CAPABLE TO BE BOUND USING THE INTERLEUKIN-6 HUMAN RECEPTOR | 2016 |
|
RU2656160C2 |
